[Meta] the receptor rule is doing its job and people should stop complaining
the receptor rule is doing its job and people should stop complaining, and here is what changes in practice if it goes ahead. Long half-life in this class comes from structural modification that promotes albumin binding and resists enzymatic degradation. Weekly dosing is a consequence of the molecule, not a…
Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.
Is that from a human study or a preclinical model?
Not convinced by the linearity assumption. Dose-response in this class is not linear and the trials show it.
What was the exposure in that experiment relative to therapeutic?
I would not read that in vitro number across to a person. The conditions are nothing like physiological.
Is that from a human study or a preclinical model?
Adding the caveat the paper itself makes in its limitations section, which is stronger than anything in this thread.